Anti-programmed cell death protein-1 (PD-1) and programmed cell death protein ligand-1 (PD-L1) agents have remarkably changed the therapeutic strategies in many cancers, such as melanoma, lung cancer, renal cell carcinoma, head and neck cancer and so on. This evidence concerns the gene CD274 and head and neck cancer.